

Supplemental Table 3: Comparison of counts of death between ClinicalTrials.gov and publication. Bolded entries indicate discrepancy in death reporting.

NCT Number	Trial Name	Arms	n	Is death or survival a primary or secondary outcome?	ClinicalTrials.gov Reporting Source	ClinicalTrials.gov Count	Publication Count
Death or Survival an Outcome Measure							
NCT00240331	AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)	2	2773	Yes (Primary) Composite	Outcome (1296) SAE (60)	1296	1296
NCT00092677	An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)	2	1873	Yes (Primary) Composite	Outcome	205	205
NCT00158600	A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease	2	90	Yes (Primary) Composite	Outcome (1) Participant Flow (1)	1	1
NCT00806403	Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction	2	205	Yes (Primary)	Outcome (7) Participant flow (7)	7	7
NCT00552669	Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eluting Stents	2	200	Yes (Secondary) Composite	Outcome (10) Participant flow	10	10
NCT00144339	Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients	2	5992	Yes (Secondary)	Outcome (941) SAE (45)	941	941
NCT00046228	A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)	3	2452	Yes (Primary) Composite	Outcome	124	124 ¥
NCT00379769	RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes	2	4447	Yes (Primary)	Outcome (299) Participant flow (250) SAE (16)	299	293
NCT00095238	Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)	2	4128	Yes (Primary) Composite	Outcome (1003) ¥ Participant flow (324) SAE (14)	1003¥	881*
NCT00105443	A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma	2	602	Yes (Primary)	Participant flow (399)‡	Reported as survival data	321±
NCT00003869	Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer	2	186	Yes (Primary)	Participant flow (3)	Reported as survival data	165
NCT00080301	Novel Etoposide Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer	2	752	Yes (Primary) Composite	Outcome (Primary) Composite SAE (3)	Reported as survival data	72
NCT00115765	PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study (oxaliplatin cohort)	2	823	Yes (Primary) Composite	Outcome	Reported as survival data	250/251 €
	PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study) (irinotecan cohort)	2	230	Yes (Primary) Composite	Outcome	44	43/44 €
NCT00075218	A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)	2	361	Yes (Secondary)	Outcome	266	Reported as Kaplan-Meier Curve

NCT Number	Trial Name	Arms	n	Is death or survival a primary or secondary outcome?	ClinicalTrials.gov Reporting Source	ClinicalTrials.gov Count	Publication Count
Deaths or Survival not an Outcome							
NCT00152763	Psychological Support for Patients With an Implantable Cardioverter Defibrillator	2	193	No	Participant Flow (8) SAE(8)	8	8
NCT00402324	A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients	2	202	No	Participant flow	1	1
NCT00852917	A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee (With 7-Day Follow-up)	4	552	No	Participant flow	1	1
NCT00479713	A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)	2	618	No	Participant flow	1	1
NCT00094458	Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease naïve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naïve Patients in Crohn's Disease: SONIC	3	508	No	Participant flow	1	1
NCT00289848	MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus	2	530	No	Participant flow	1	1
NCT00285012	Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).	2	499	No	Participant flow	3	3
NCT00132808	Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older	3	581	No	Participant flow	1	1
NCT00127712	Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery	2	130	No	SAE	3	3
NCT00313313	A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas	3	768	No	Participant flow	2	1
NCT00092521	Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)	3	5455	No	Participant flow	3	4
NCT00441545	Head to Head Study Against Sevelamer Hydrochloride	2	182	No	SAE	1	Not reported
NCT00463866	Local Phase 4 Pan-European SMART Study	2	8053	No	SAE	2	4
NCT00489736	Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation	2	504	No	SAE	1	7
NCT00081770	Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471AM1)(COMPLETED)	3	3070	No	SAE	1	12

¥ Estimated from percentages.

*Discrepancy due to use of different follow-up periods.

‡ Deaths reported in Participant Flow Section sub-divided by if participant continued on to open-label follow-up. It is not possible to calculate deaths occurring during double-blind study period.

± Publication reports the numbers used for the 2nd interim analysis. Both sources report survival data consistently. In ClinicalTrials.gov, hazard ratio for overall survival at October 17,2006 cutoff date reported as 0.69 (0.55 to 0.87). In publication, hazard ratio reported for same cutoff date as 0.69 (0.55 to 0.87).

€ Discrepancy in deaths reported within publication. Within plot of overall survival, 251 and 44 deaths reported for oxaliplatin and irinotecan based-cohorts respectively. In text, 250 and 43 deaths reported respectively.